Discovery and preclinical characterization of orally bioavailable JAK2V617F mutant selective JH2 inhibitors with disease modification potential in myeloproliferative neoplasms
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Neha Bhagwat, Duanya Liu, Xiaowei Wu, Alexander Grego, Amy Crossan, Andrew Moore, Arpita Mondal, Carly Bachner, Diego Elrio, Dani Roth, John Rose, Joseph Rager, Joy Cote, Kirsten Gallagher, Klare Bersch, Miles Cowart, Natalie Kurtz, Angelina DiBiaso, Maggie Sumerau, Olusola Osinubi, Min Wang, Sharayu Chandratre, Song Mei, Srijita Dhar, Stephanie Rodgers, Sushanta Ratna, Yann Loret, Yue Zou, Sandy Geeganage, Andrew Combs, Jean-Jacques Kiladjian, Stephane Giraudier, Peggy Scherle
Institutions: Prelude Therapeutics Incorporated (United States), Inserm
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7108445837